Daniel Pollyea
@DanPollyea
Followers
2K
Following
3K
Media
23
Statuses
1K
The Leukemologist
Denver, Colorado
Joined October 2012
CU Cancer Center member Mathew Angelos, MD, PhD, (@Mat_Angelos) is helping lead the first human trial of a homegrown novel CAR T-cell therapy for an aggressive, hard-to-treat form of leukemia ⬇️ https://t.co/lmU8XP4ljJ
news.cuanschutz.edu
A physician-scientist who last year joined the CU Cancer Center team will soon steer the first human trial of a homegrown CAR T-cell therapy for leukemia.
0
2
7
Incredibly exciting times for our pts & AML field with the 2nd menin inhibitor- Ziftomenib- now approved for R/R NPM1m AML. Kudos & congratulations to all investigators on the KOMET studies. Looking forward to future combination Tx strategies. 👏👏👏
Ziftomenib is now @US_FDA ✅ for R/R AML w/ NPM1 mutation (based off KOMET-001): - mOS 6.1mos - mOS significantly better in “responders” - 35% ORR #HemeTwitter @EuniceWangMD @RoswellPark @GhayasIssa 👏👏
2
7
37
Fantastic Grand Rounds seminar by @MikkaelSekeres about the myriad machinations of MDS @UNCDeptMedicine @UNC_Lineberger. Such an inspiring and incredible speaker and grateful our Leukemia team got to meet Mikkael. Thanks for spending time with us in Chapel Hill @MikkaelSekeres
1
2
28
So great to spend time with @MikkaelSekeres in Chapel Hill discussing all things myeloid! Looking forward to having him meet our Division tomorrow for Hematology Grand Rounds @UNCDeptMedicine @UNC_Lineberger
2
2
21
Hanging out in San Diego today and tomorrow? Come join us at #NCCNhem25 annual meeting! Outstanding first session on care coordination with community and academic practices. @DanPollyea @Daver_Leukemia
0
3
16
Denver @Broncos passing game specialist Zack Grossi (@ZackG13) is cancer-free after undergoing treatment for a yolk sac tumor with providers at the CU Cancer Center ⬇️ https://t.co/noycQd1mc9
news.cuanschutz.edu
Diagnosed with a yolk sac tumor in 2024, Denver Broncos coach Zack Grossi was treated by Laura Graham, MD, after a chance meeting in the ER.
0
1
12
☀️ Sunshine State Sunday Spotlight! Join us in Orlando before #ASH25 for Medical Crossfire®: Experts Debate AML🔥 📅 Dec 5, 2025 | 📍 Orlando, FL FLT3, IDH1/2, KMT2Ar, NPM1, secondary AML & more! Register now. https://t.co/IpxTf9lYxy
@Dr_AmerZeidan @Daver_Leukemia @DanPollyea
0
4
7
Welcome new faculty Dr. Thomas Kartika to CU Hematology and to *the most gorgeous* of all the United States: COLORADO. 🌞🌄❄️🍂We are happy you are here!
0
3
7
The #NashvilleHeme26 Poster Competition is officially open! Share your research, get recognized, and join leaders in hematology at the 2-day CE-accredited conference. Abstracts are due October 10 — don’t miss it: https://t.co/KWayjAmYgA
#HemeOnc #HematologyResearch #OncTwitter
0
5
13
#BloodCancerAwarenessMonth: CU Cancer Center member Christine McMahon, MD, discusses the various types of blood cancers treated at the center. You can learn more about blood cancer here: https://t.co/41oTeG2YtZ
0
3
9
Totally humbled by your generosity @DanPollyea, especially coming from someone as inspiring as you! 😊🙏
ASH elections ballots were sent out today. I am voting for @MikkaelSekeres for councilor! Mikkael is a tremendous mentor to so many of us, and an invaluable advocate for all things Hematology. The future of ASH will be in great hands with his leadership.
0
2
21
ASH elections ballots were sent out today. I am voting for @MikkaelSekeres for councilor! Mikkael is a tremendous mentor to so many of us, and an invaluable advocate for all things Hematology. The future of ASH will be in great hands with his leadership.
0
2
19
Dr. @BradHaverkos @CUHematology contributed to a @CIBMTR study of CD19 CAR-T for PMBCL, now published @AjHematology. Two-year PFS 59% and two-year OS 81%, with two-year cumulative incidence of relapse at 36%. #lymsm #tcellrx
0
3
18
Dr. Andrew Kent from @CUHematology and @CUCancerCenter is leading a trial testing if mitoxantrone can help AML patients resistant to current treatments. This could change leukemia care. 🌟 https://t.co/iyhNMInKxT
#CancerResearch #MedTwitter
news.cuanschutz.edu
Expanding on previous research, Andrew Kent, MD, PhD, is leading a clinical trial to investigate whether a drug can reduce resistance to an AML treatment.
0
5
11
#IntheSpotlight A FABulous Couple: Adding PHENotype to GENotype Improves HMA/VEN Response Prediction in AML https://t.co/PqCzQD264b
1
13
38
#OnlineFirst Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study https://t.co/MEpQm7xUNc
0
3
6
When a CT scan revealed a mass on his bladder, @CUBoulder football coach Deion "Coach Prime" Sanders was referred to #CUAnschutz – a national leader in #bladdercancer care – where he met with Janet Kukreja, MD, director of urologic oncology at @CUCancerCenter and @uchealth.
1
8
34
@sanamloghavi @PapaemmanuilLab Thank you, @sanamloghavi and @PapaemmanuilLab for the opportunity. The best part is working with all the individuals who collaborated on this project.
0
1
9
Awesome work congratulations!!
Happy to share our newest work out today in BCD evaluating disease classification and prognosis in the “world of myeloid malignancies”! Wonderful collaboration with @sanamloghavi @PapaemmanuilLab @Elsa2Bernard and colleagues.
2
1
7
Happy to share our newest work out today in BCD evaluating disease classification and prognosis in the “world of myeloid malignancies”! Wonderful collaboration with @sanamloghavi @PapaemmanuilLab @Elsa2Bernard and colleagues.
Online First: Multi-Modal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States https://t.co/b1pFKU7THa
5
14
51